Key result
Right atrial bypass grafting for hemodialysis-related central venous occlusive disease resulted in a mean primary patency of 8.1 months, secondary patency of 21.7 months, and 4% 30-day mortality.
Why the study?
Central venous occlusive disease in hemodialysis patients requires frequent re-interventions, prompting an evaluation of the indications, technical aspects, and outcomes of right atrial bypass grafting.
What are the outcomes and patency rates of right atrial bypass grafting in hemodialysis patients with central venous occlusive disease?
Systematic Review (n=55)
What are the outcomes and patency rates of right atrial bypass grafting in hemodialysis patients with central venous occlusive disease?
Right atrial bypass grafting may serve as a viable last-resort option for hemodialysis patients with central venous occlusive disease when conventional treatments are exhausted, offering acceptable secondary patency despite a 4% 30-day mortality.
INTRODUCTION: Central venous occlusive disease (CVOD) is a complication that can occur in patients with end-stage renal disease who are receiving hemodialysis. When CVOD develops, patients often require multiple re-interventions to maintain their dialysis access. CVOD can be treated by various strategies such as balloon angioplasty, stenting, lower limb or extra-anatomical grafts, hybrid grafts or surgical bypasses such as right atrial (RA). In this systematic review, we aim to evaluate the indications, technical aspects, and outcomes after RA bypass grafting for the treatment of CVOD in hemodialysis patients. METHODS: A systematic and comprehensive literature search was conducted using various electronic databases. We included articles that reported described and reported outcomes of RA bypass grafting for the treatment of CVOD in hemodialysis patients. A narrative review of the indications and technical aspects of RA bypass grafting was performed. We also pooled and reported the primary patency, secondary patency, postoperative complications, and 30-day mortality of RA bypass grafting. RESULTS: A total of 21 studies with 55 patients who underwent RA bypass grafting were included in our systematic review. Follow-up period ranged from 0.5 to 84 months. The mean pooled primary patency and secondary patency of RA bypass grafting were 8.1 ± 4.9 and 21.7 ± 20.1 months, respectively. The incidence of early postoperative complications such as surgical site infection, bleeding, and access thrombosis was 0%, 4%, and 4%, respectively. The overall 30-day mortality was 4%. CONCLUSIONS: This systematic review summarizes the patient characteristics, technical features and outcomes of RA bypass grafting in the treatment of hemodialysis-related CVOD. RA bypass grafting may be a viable last-resort option when less invasive or conventional treatment options have been exhausted.
No takes yet. Share an insight, caveat, or question.
Paik et al. (2022) conducted a systematic review in Central venous occlusive disease in patients undergoing hemodialysis (n=55). Right atrial bypass grafting was evaluated on Primary patency (months). Right atrial bypass grafting for hemodialysis-related central venous occlusive disease resulted in a mean primary patency of 8.1 months, secondary patency of 21.7 months, and 4% 30-day mortality.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: